CORDIS
EU research results

CORDIS

English EN

A novel generation of skin substitutes to clinically treat a broad spectrum of severe skin defects

Objective

Large full-thickness skin defects resulting from burns, soft tissue trauma, congenital giant nevi, tumour resection, and disease leading to skin necrosis, represent a significant and common clinical problem worldwide. This problem is far from being solved. The main challenge encountered is that most autologous skin grafting techniques are based on transplanting split-thickness skin (the today’s gold standard). Split-thickness skin contains all of the epidermis, but only remnants of the dermis. This lack of dermal tissue, frequently leads to significant scarring. Consequently, a true dermal substitute is required, which instantly exerts the cell-instructive properties of a neo-dermis. The partners of EuroSkinGraft can now offer 2 dermal substitutes, Novomaix and denovoDerm, plus the dermo-epidermal skin substitute denovoSkin. The development of all 3 substitutes was significantly supported by the FP6-program (EuroSTEC). The envisaged clinical studies are aiming strictly at a one-step surgical procedure (instead of the common two-step procedure, using Integra Artificial Skin).This is to be reached with the following protocol:
Clinical application of Novomaix
1. Experimental arm 1: split-thickness skin on Novomaix applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
Clinical application of denovoDerm
1. Experimental arm 1: split-thickness skin on denovoDerm applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
Clinical application of denovoSkin
1. Experimental arm 1: denovoSkin applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
The strength of this project lies in: the high degree to which real regenerative medicine is translated into the clinic, the innovative and highly functional character of the 3 products to be tested, the central contribution of the 3 SMEs, and the excellence of the 3 clinics.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAT ZURICH

Address

Ramistrasse 71
8006 ZÜRich

Switzerland

Activity type

Other

EU Contribution

€ 3 020 144,34

Administrative Contact

Ernst Reichmann (Dr.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Netherlands

VEREIN FUER BERUFSGENOSSENSCHAFTLICHE HEILBEHANDLUNG BERLIN EV

Germany

EU Contribution

€ 726 060

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 425 580

MATRICEL GMBH

Germany

EU Contribution

€ 302 520

THE MEDICAL DEVICE CO LTD

United Kingdom

EU Contribution

€ 402 930

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 209 919,76

STICHTING VUMC

Netherlands

EU Contribution

€ 874 852

ARTTIC

France

EU Contribution

€ 34 011,90

STICHTING VU

Netherlands

Project information

Grant agreement ID: 279024

Status

Closed project

  • Start date

    1 October 2011

  • End date

    30 September 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 875 214,54

  • EU contribution

    € 5 996 018

Coordinated by:

UNIVERSITAT ZURICH

Switzerland

This project is featured in...